Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study.
BioDrugs. 2020 Dec;34(6):809-823. doi: 10.1007/s40259-020-00447-6.
BioDrugs. 2020.
PMID: 33119861
Free PMC article.